to win business from both emerging biotech firms and large pharma clients seeking partners with specialized skills. “The group is a well-established player in this CDMO field,” Angioletti said. “It’s a company with strong roots in respect, transparency, service, and speed of execution. We have a long vision, up to five and ten years, and have plans for investments in that direction.” For Mossi, the goal remains straightforward: “A Swiss centre of excellence serving the pharmaceutical world of CDMO. That’s our target for the coming years.” As Angioletti put it: “When you see clients returning time and again, it means you are doing something right.” HAS and Cerbios will be present at CPHI Frankfurt from October 28–30, where it will highlight the group’s expanded capabilities following the merger. Executives will be available to meet clients and partners at booths 9.1D77 and 9.1F77. By sequencing investments step by step, the group aims to remain flexible while avoiding overextension. Risks and discipline The CDMO sector’s strong growth also brings a unique set of challenges. Facilities for biologics and ADCs require vast capital outlays and lengthy regulatory approvals. If demand falters, underutilized assets can quickly erode margins. HAS and Cerbios believe their focused approach mitigates this risk. “Specifically for ADCs, there are many investments ongoing and others planned to increase our capacity in terms of linker payload and conjugation,” Mossi said. “We want to become a leader in ADC development and manufacturing.” Angioletti stressed prudence: “We are not one of those companies shooting out investment and doing things. We do tailor-made what is necessary, step by step, but in advance, in order to keep the speed and the capacity in our services.” Looking ahead This union positions HAS and Cerbios to capture opportunities in a sector expected to double in size within the decade. By combining chemistry, biologics, and regulatory expertise, the group aims HAS - CERBIOS WILL CHU Editorial team 24/7 BIOPHARMA 26CPHI FRANKFURT 2025 PREVIEW
RkJQdWJsaXNoZXIy MjY2OTA4MA==